These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18799822)

  • 1. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats.
    Al-Salami H; Butt G; Tucker I; Mikov M
    Pharmacol Rep; 2008; 60(4):532-41. PubMed ID: 18799822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics.
    Al-Salami H; Butt G; Tucker I; Mikov M
    Methods Find Exp Clin Pharmacol; 2008 Mar; 30(2):107-13. PubMed ID: 18560625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.
    Al-Salami H; Butt G; Tucker I; Fawcett PJ; Golocorbin-Kon S; Mikov I; Mikov M
    Eur J Drug Metab Pharmacokinet; 2009; 34(1):43-50. PubMed ID: 19462928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.
    Mikov M; Al-Salami H; Golocorbin-Kon S; Skrbic R; Raskovic A; Fawcett JP
    Eur J Drug Metab Pharmacokinet; 2008; 33(3):137-42. PubMed ID: 19007038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
    Al-Salami H; Butt G; Tucker I; Golocorbin-Kon S; Mikov M
    Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):99-108. PubMed ID: 21874525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats.
    Mikov M; Boni NS; Al-Salami H; Kuhajda K; Kevresan S; Golocorbin-Kon S; Fawcett JP
    Eur J Drug Metab Pharmacokinet; 2007; 32(1):7-12. PubMed ID: 17479538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.
    Al-Salami H; Butt G; Tucker I; Skrbic R; Golocorbin-Kon S; Mikov M
    Arch Drug Inf; 2008 Jul; 1(1):35-41. PubMed ID: 20157366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques.
    Mariappan TT; Singh S
    Mol Pharm; 2004; 1(5):363-7. PubMed ID: 16026006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
    Golocorbin-Kon S; Calasan J; Milijasevic B; Vukmirovic S; Lalic-Popovic M; Mikov M; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):1005-1011. PubMed ID: 28547295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed Micelles Loaded with Bile Salt: An Approach to Enhance Intestinal Transport of the BCS Class III Drug Cefotaxime in Rats.
    Arafat M; Kirchhoefer C; Mikov M
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):635-645. PubMed ID: 27686853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats.
    Al-Salami H; Butt G; Fawcett JP; Tucker IG; Golocorbin-Kon S; Mikov M
    Eur J Drug Metab Pharmacokinet; 2008; 33(2):101-6. PubMed ID: 18777945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study.
    Teofilovic B; Golocorbin-Kon S; Stilinovic N; Grujic-Letic N; Raškovic A; Mooranian A; Al-Salami H; Mikov M
    Sci Rep; 2021 Nov; 11(1):22123. PubMed ID: 34764416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat.
    Golocorbin-Kon S; Mikov M; Arafat M; Lepojevic Z; Mikov I; Sahman-Zaimovic M; Tomic Z
    Eur J Drug Metab Pharmacokinet; 2009; 34(1):31-6. PubMed ID: 19462926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats.
    Rasković A; Mikov M; Skrbić R; Jakovljević V; Vasović V; Posa M; Kuhajda K; Kevresan S; Tomic Z; Siladji D
    Eur J Drug Metab Pharmacokinet; 2008; 33(1):17-22. PubMed ID: 18543580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes.
    Kinukawa J; Shimura M; Harata N; Tamai M
    Curr Eye Res; 2005 Sep; 30(9):789-98. PubMed ID: 16146925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
    Tanira MO; Furman BL
    Pharmacol Res; 1999 May; 39(5):349-56. PubMed ID: 10328992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1508-19. PubMed ID: 26212118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular permeability with sulfonylureas in normal and diabetic hamsters.
    Bouskela E; Cyrino FZ; Conde CM; Garcia AA
    Metabolism; 1997 Dec; 46(12 Suppl 1):26-30. PubMed ID: 9439555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.
    Aungst BJ; Saitoh H
    Pharm Res; 1996 Jan; 13(1):114-9. PubMed ID: 8668658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
    Saitoh H; Aungst BJ
    Pharm Res; 1995 Sep; 12(9):1304-10. PubMed ID: 8570526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.